Related Experiment Video
Updated: Jan 1, 2026
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
8.0K
LINC00958 Accelerates Cell Proliferation and Migration in Non-Small Cell Lung Cancer Through JNK/c-JUN Signaling
Zhigang Luo1, Zhiyi Han2, Feng Shou1
1Department of Oncology, The People's Hospital of Jianyang City, Jianyang, Sichuan Province, China.
Human Gene Therapy Methods
|December 20, 2019
Summary
Long non-coding RNA LINC00958 promotes non-small cell lung cancer (NSCLC) by activating the JNK/c-JUN pathway. This finding offers a potential new avenue for NSCLC diagnosis and treatment.
Area of Science:
- Molecular Oncology
- Cancer Biology
- Non-coding RNA Research
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
- Long non-coding RNAs (lncRNAs) are implicated in cancer development, but their specific roles in NSCLC remain unclear.
- LINC00958 is a newly identified intergenic lncRNA with potential involvement in NSCLC pathogenesis.
Purpose of the Study:
- To investigate the role of the lncRNA LINC00958 in the development of non-small cell lung cancer (NSCLC).
- To elucidate the underlying molecular mechanisms by which LINC00958 influences NSCLC progression.
- To explore the potential of LINC00958 as a diagnostic or therapeutic target for NSCLC.
Main Methods:
- Bioinformatic analysis of online databases to assess LINC00958 expression in lung tissues and cell lines.
- Experimental manipulation of LINC00958 levels (knockdown) in lung adenocarcinoma (LUAD) cells.
- Assessment of cellular proliferation, apoptosis, and migration following LINC00958 knockdown.
- Investigation of the involvement of the JNK/c-JUN signaling pathway in LINC00958-mediated effects.
Main Results:
- LINC00958 was found to be upregulated in LUSC tissues and both LUAD and LUSC cell lines compared to normal lung cells.
- Knockdown of LINC00958 inhibited proliferation, induced apoptosis, and reduced migration in LUAD cells.
- LINC00958 promotes LUAD by activating the JNK signaling pathway, enhancing c-JUN transactivation, and is transcriptionally regulated by c-JUN.
- These findings were consistent in both LUAD and LUSC cell types.
Conclusions:
- LINC00958 acts as an oncogenic lncRNA in non-small cell lung cancer (NSCLC).
- LINC00958 facilitates tumorigenesis by activating the JNK/c-JUN signaling pathway.
- LINC00958 represents a potential novel biomarker and therapeutic target for NSCLC, including LUAD and LUSC.
Related Concept Videos
01:07MAPK Signaling Cascades
7.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
01:19Interactions Between Signaling Pathways
7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
02:39lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
01:22PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K